Defined transcription factors can induce epigenetic reprogramming of adult mammalian cells into induced pluripotent stem cells. Although DNA factors are integrated during some reprogramming methods, it is unknown whether the genome remains unchanged at the single nucleotide level. Here we show that 22 human induced pluripotent stem (hiPS) cell lines reprogrammed using five different methods each contained an average of five protein-coding point mutations in the regions sampled (an estimated six protein-coding point mutations per exome). The majority of these mutations were non-synonymous, nonsense or splice variants, and were enriched in genes mutated or having causative effects in cancers. At least half of these reprogramming-associated mutations pre-existed in fibroblast progenitors at low frequencies, whereas the rest occurred during or after reprogramming. Thus, hiPS cells acquire genetic modifications in addition to epigenetic modifications. Extensive genetic screening should become a standard procedure to ensure hiPS cell safety before clinical use.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sequence Read Archive
Sequencing results for the mutations reported here are included in Supplementary Figure 1. Raw Illumina sequencing reads are available from the NCBI ShortRead Archive, accession SRP005709, except for lines derived from Hib11, Hib17, Hib29, CF, HFFxF, dH1F fibroblasts as the original donors were not consulted about public release of their genome data.
We thank J. M. Akey, G. M. Church, S. Ding, J. B. Li and J. Shendure for discussions and suggestions, S. Vassallo for assistance with DNA shearing, and G. L. Boulting and S. Ratansirintrawoot for assistance with hiPS cell culture. This study is supported by NIH R01 HL094963 and a UCSD new faculty start-up fund (to K.Z.), a training grant from the California Institute for Regenerative Medicine (TG2-01154) and a CIRM grant (RC1-00116) (to L.S.B.G.). L.S.B.G. is an Investigator of the Howard Hughes Medical Institute. A. Gore is supported by the Focht-Powell Fellowship and a CIRM predoctoral fellowship. M.L.W. is supported by an institutional training grant from the National Institute of General Medical Sciences (T32 GM008666). Y.-H.L. is supported by the A*Star Institute of Medical Biology and the Singapore Stem Cell Consortium. Work in the laboratory of J.C.I.B. was supported by grants from MICINN, Sanofi-Aventis, the G. Harold and Leila Y. Mathers Foundation and the Cellex Foundation. G.Q.D. is an investigator of the Howard Hughes Medical Institute and supported by grants from the NIH.
The file contains Supplementary Tables 1-3
About this article
Nature Protocols (2018)